Status:
COMPLETED
Clinical Validation Protocol for BCI for the Communication of Patients Suffering From Neuromuscular Disorders.
Lead Sponsor:
Centre d'Investigation Clinique et Technologique 805
Collaborating Sponsors:
Association Française contre les Myopathies (AFM), Paris
Conditions:
Communication
Neuromuscular Disease
Eligibility:
All Genders
18+ years
Brief Summary
the objective of this protocol is evaluate the safety and tolerance of a communication system for severely disable patients with myopathies. The system analyses the brain electric activity in real tim...
Detailed Description
This is a pilot study for which 15 patients with myopathies will be included. The primary objective of the study is to assess the safety and tolerance of a system for communication named P300 speller....
Eligibility Criteria
Inclusion
- Adult older than 18y.o., diagnosed with neuromuscular disease, stable vital signs and informed consent
Exclusion
- History of seizure, brain damage, sight or auditory dysfunction, Atopic dermatitis, skin hypersensitivity to gold, patient under guardianship, illiterates or not able to cooperate , cognitive dysfunction
- Steinert disease, Merosine negative disease, Alpha-dystroglycanopathies
Key Trial Info
Start Date :
October 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2017
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT02284022
Start Date
October 1 2014
End Date
February 1 2017
Last Update
April 20 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital R. Poincaré
Garches, France, 92380